Myriad Genetics, Inc. (MYGN)'s Prolaris(R) Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy
2/3/2012 9:53:51 AM
SALT LAKE CITY, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday, February, 2, 2012 at the 2012 Genitourinary Cancers Symposium. The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.
comments powered by